Drugs / LUCAR-B68
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05498545 | Nov 2022 → May 2025 | refractory plasma cell neoplasm | Second Affiliated Hospital of Xi'an Jiaotong University | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-B68 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498545 ↗ |
| Modality | Cell therapy | “LUCAR-B68 cell preparations” NCT05498545 ↗ |